<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701844</url>
  </required_header>
  <id_info>
    <org_study_id>GCO #06-0391 (2)</org_study_id>
    <secondary_id>RSGPB-07-285-01-CPPB</secondary_id>
    <nct_id>NCT00701844</nct_id>
  </id_info>
  <brief_title>Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors</brief_title>
  <official_title>Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sharing Our Strength study is being conducted to help us understand people's experiences
      with hematopoietic stem cell transplantation and to test a new program designed to help
      people recover physically and emotionally after transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study for survivors of hematopoietic stem cell transplantation (also known as bone
      marrow transplant), which is an intensive medical treatment for cancers such as leukemia,
      lymphoma, and multiple myeloma as well as other diseases. Because it is a physically and
      emotionally demanding treatment, many people report having ongoing physical and emotional
      difficulties after having a transplant. The Sharing Our Strength study is being conducted to
      help us understand people's transplant experiences and to test a new program designed to help
      them recover physically and emotionally after transplant. All parts of the study are
      completed by mail and telephone. Participants will receive compensation for their time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychological Adjustment</measure>
    <time_frame>At screening, baseline and 3 months following intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>At screening, baseline and 3 months following intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">315</enrollment>
  <condition>Leukemia</condition>
  <condition>Acute Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Hematological Cancers</condition>
  <condition>Psychological Distress</condition>
  <arm_group>
    <arm_group_label>Experimental Writing Type 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Writing type 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control writing type 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control writing type 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Writing A (Experimental informative writing)</intervention_name>
    <description>Experimental informative writing</description>
    <arm_group_label>Experimental Writing Type 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Writing B (Experimental noninformative writing)</intervention_name>
    <description>Experimental noninformative writing</description>
    <arm_group_label>Experimental Writing type 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Writing C (Control informative writing)</intervention_name>
    <description>Control informative writing</description>
    <arm_group_label>Control writing type 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Writing D (Control noninformative writing)</intervention_name>
    <description>Control noninformative writing</description>
    <arm_group_label>Control writing type 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a transplant survivor who is 9 months to 3 years beyond transplant and not
             currently relapsed. and not currently relapsed

          -  Be at least 18 years old now (and at least 16 when they had their transplant)

          -  Speak English

          -  Have telephone service

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Rini, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601-1991</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-6011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aplastic Anemia</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Leukemia, Lymphoid</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Precursor Cell Lymphoblastic Leukemia-Lymphoma</keyword>
  <keyword>Anemia</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

